Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of ZD1839 (Iressa)in Chemotherapy Refractory Germ Cell Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

NCT00198159 is registered in ClinicalTrials.gov with Indiana University as lead sponsor.

NCT NCT00198159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00198159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of ZD1839 (Iressa)in Chemotherapy Refractory Germ Cell Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Lead sponsor
Indiana University
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2002
Completion date
March 31, 2006
Enrollment
21
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory germ cell tumors expressing egrf